HMGB1 and arthritic joint disease: In particular, in two notably different models of arthritis, collagen-induced arthritis (CIA) and a genetic model of arthritis, Schierbeck and colleagues demonstrated that anti-HMGB1 monoclonal antibody administration significantly ameliorated the clinical courses in these experimental conditions.